Pentixafor

Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging[1][2][3][4]. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Product Specifications

CAS Number

[1341207-62-2]

UNSPSC

12352209

Target

CXCR; Radionuclide-Drug Conjugates (RDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/pentixafor.html

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic) |Methanol : ≥ 125 mg/mL

Smiles

O=C(NCC(N[C@@H](C1=O)CC(C=C2)=CC=C2O)=O)[C@@H](NC([C@@H](NC([C@H](N1C)CCCNC(C(C=C3)=CC=C3CNC(CN(CCN(CC4)CC(O)=O)CCN(CCN4CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)=O)CC5=CC(C=CC=C6)=C6C=C5

Molecular Formula

C60H80N14O14

Molecular Weight

1221.36

References & Citations

[1]Buck AK, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022 Oct;49 (12) :4133-4144. |[2]Schwarzenböck SM, et al. [68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression. Oncotarget. 2017 Sep 16;8 (56) :95606-95619.|[3]Chen Z, et al. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease. Mini Rev Med Chem. 2023;23 (7) :787-803.|[4]Poschenrieder A, et al. First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. Tomography. 2016 Jun;2 (2) :85-93.